BECKMANN AND LINGS OBSTETRICS
AND GYNECOLOGY 8TH EDITION
ROBERT CASANOVA TESTED QUESTIONS
AND COMPLETE SOLUTIONS
◉ Preeclampsia
Answer: Hypertension after 20 weeks with proteinuria and/or
organ involvement; course slides emphasize vasospasm and poor
tissue perfusion.
◉ Preeclampsia warning signs
Answer: Persistent headache, blurred/visual changes, epigastric
or RUQ pain, facial/periorbital edema, and breathing difficulty.
◉ Magnesium sulfate purpose
Answer: Prevents eclamptic seizures; may also be used as a
tocolytic/fetal neuroprotection. It does NOT primarily lower
blood pressure.
◉ Magnesium sulfate loading dose
Answer: 4-6 g IV over 20 minutes per course slides.
◉ Magnesium sulfate maintenance dose
Answer: 1-2 g/hr per course slides.
,◉ Therapeutic magnesium level
Answer: 4-7 mg/dL per course slides.
◉ Expected magnesium sulfate effects
Answer: Flushing/warmth, headache, and lethargy.
◉ Magnesium sulfate toxicity
Answer: Markedly decreased/absent deep tendon reflexes and
respiratory depression.
◉ Magnesium sulfate nursing monitoring
Answer: Monitor respiratory rate, DTRs, urine output, LOC, fetal
status, and serum magnesium.
◉ Magnesium sulfate antidote
Answer: IV calcium gluconate.
◉ Terbutaline
Answer: Tocolytic that may cause maternal tachycardia and
hyperglycemia; use cautiously in diabetes.
◉ Oxytocin
, Answer: Stimulates uterine contractions; requires fetal heart rate
and contraction monitoring.
◉ Tachysystole
Answer: More than 5 contractions in 10 minutes.
◉ Oxytocin with tachysystole
Answer: Stop oxytocin and continue fetal monitoring; severe cases
may require a tocolytic.
◉ Methylergonovine (Methergine)
Answer: Uterotonic used for postpartum hemorrhage; avoid in
hypertension/preeclampsia.
◉ GDM screening
Answer: Routine gestational diabetes screening occurs at 24-28
weeks.
◉ GDM management
Answer: Diet/exercise, glucose monitoring, insulin if needed, and
fetal surveillance such as ultrasound/NST/BPP.
◉ Newborn hypoglycemia risk factors
Answer: Maternal diabetes, prematurity, SGA, LGA, cold stress, or
asphyxia.
AND GYNECOLOGY 8TH EDITION
ROBERT CASANOVA TESTED QUESTIONS
AND COMPLETE SOLUTIONS
◉ Preeclampsia
Answer: Hypertension after 20 weeks with proteinuria and/or
organ involvement; course slides emphasize vasospasm and poor
tissue perfusion.
◉ Preeclampsia warning signs
Answer: Persistent headache, blurred/visual changes, epigastric
or RUQ pain, facial/periorbital edema, and breathing difficulty.
◉ Magnesium sulfate purpose
Answer: Prevents eclamptic seizures; may also be used as a
tocolytic/fetal neuroprotection. It does NOT primarily lower
blood pressure.
◉ Magnesium sulfate loading dose
Answer: 4-6 g IV over 20 minutes per course slides.
◉ Magnesium sulfate maintenance dose
Answer: 1-2 g/hr per course slides.
,◉ Therapeutic magnesium level
Answer: 4-7 mg/dL per course slides.
◉ Expected magnesium sulfate effects
Answer: Flushing/warmth, headache, and lethargy.
◉ Magnesium sulfate toxicity
Answer: Markedly decreased/absent deep tendon reflexes and
respiratory depression.
◉ Magnesium sulfate nursing monitoring
Answer: Monitor respiratory rate, DTRs, urine output, LOC, fetal
status, and serum magnesium.
◉ Magnesium sulfate antidote
Answer: IV calcium gluconate.
◉ Terbutaline
Answer: Tocolytic that may cause maternal tachycardia and
hyperglycemia; use cautiously in diabetes.
◉ Oxytocin
, Answer: Stimulates uterine contractions; requires fetal heart rate
and contraction monitoring.
◉ Tachysystole
Answer: More than 5 contractions in 10 minutes.
◉ Oxytocin with tachysystole
Answer: Stop oxytocin and continue fetal monitoring; severe cases
may require a tocolytic.
◉ Methylergonovine (Methergine)
Answer: Uterotonic used for postpartum hemorrhage; avoid in
hypertension/preeclampsia.
◉ GDM screening
Answer: Routine gestational diabetes screening occurs at 24-28
weeks.
◉ GDM management
Answer: Diet/exercise, glucose monitoring, insulin if needed, and
fetal surveillance such as ultrasound/NST/BPP.
◉ Newborn hypoglycemia risk factors
Answer: Maternal diabetes, prematurity, SGA, LGA, cold stress, or
asphyxia.
